Stockreport

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Viru...

Aligos Therapeutics, Inc. - Common stock  (ALGS) 
PDF Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fu [Read more]